Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0304 • ACR Convergence 2025
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Takahisa Gono¹, Vidya Limaye², Latika Gupta³, Vikas Agarwal⁴, Ho So⁵, JASMIN RAJA⁶, Warren Weng Seng Fong⁷, Suparaporn Wangkaew⁸, Andrea Low⁹, Akihiro Murakami¹⁰, Kimiko Hasegawa¹⁰, Takuya Isayama¹¹ and Masataka Kuwana¹, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶University Malaya, Subang Jaya, Malaysia, ⁷Singapore General Hospital, Singapore, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, ⁹Singapore General Hospital, Singapore, Singapore, ¹⁰Medical & Biological Laboratories co., ltd., Tokyo, ¹¹Medical & Biological Laboratories co., ltd., Tokyo, Japan
Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
Abstract Number: 0617 • ACR Convergence 2025
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Kathryn Counts¹, Dulaney Wilson², Leon Furchtgott³ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³SeraNova Bio, Boston, MA
Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
Abstract Number: 1033 • ACR Convergence 2025
Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
Tien-Ming Chan, Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China)
Background/Purpose: ANA prevalence and patterns vary in RA. Using ICAP nomenclature, this study aimed to determine the prevalence of RA across different ANA patterns and…
Abstract Number: 1570 • ACR Convergence 2025
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Francesco Bonomi¹, Ilaria Bisconti², Ilenia Mallia³, Greta Pellegrino⁴, Gabriele Ciuti⁵, Gloria Muolo², Martina Salerno², Simona Truglia², Cristiano Barbetta³, Silvia Peretti⁵, Serena Guiducci⁶, Valeria Riccieri⁷ and Silvia Bellando Randone³, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²Sapienza University of Rome, Rome, Rome, Italy, ³University of Florence, Florence, Italy, ⁴Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁵University Hospital Careggi, Florence, Italy, ⁶Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ⁷Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…
Abstract Number: 2058 • ACR Convergence 2025
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
valeria cantu¹, Emmanuel Dominguez-Chapa², Rebeca L. Polina-Lugo¹, Ana Cecilia Bardan Inchaustegui³, fernanda m. garcia-Carrillo⁴, Ericka S. Reyna-Hernandez⁵, Daniela A. Mejia-Rodriguez⁵, Rosa Arvizu-Rivera⁶, Jesus Alberto Cardenas-de la Garza⁷, Miguel Villarreal-Alarcón⁸ and Dionicio A. Galarza-Delgado⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
Abstract Number: 2422 • ACR Convergence 2025
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
Oihane Ibarguengoitia-Barrena¹, Leyre Riancho Zarrabeitia², Iñigo Rúa-Figueroa³, Karen Roberts⁴, Victor Martinez-Taboada⁵, Raúl Menor Almagro⁶, Belén Serrano-Benavente⁷, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernández-Nebro¹⁰, Maria Esther Ruiz Lucea¹¹, Jaime Calvo¹², Jose Francisco Garcia Llorente¹³, EVA GLORIA TOMERO MURIEL¹⁴, Maria Esther Uriarte¹⁵, Mercedes Freire González¹⁶, Angela Pecondón-Español¹⁷, Javier García-Fernández¹⁸, Lorena Expósito-Pérez¹⁹, Monica Ibañez Barcelo²⁰, Elena Aurrecoechea²¹, Carlos Montilla²², Jose Rosas Gómez de Salazar²³, Maria Garcia-Villanueva²⁴, Rocío Caño²⁵, Francisco Javier Toyos²⁶, Francisco Javier Novoa²⁷, Clara Moriano²⁸, Gema Bonilla²⁹, Javier Narváez³⁰, Jose Luis Andreu³¹, Marta Arévalo-Salaet³², Loreto Horacda-Rubio³³, Tatiana Cobo-Ibáñez³⁴, Nuria Lozano Rivas³⁵, Cristina Bohorquez³⁶, Carlota Laura Iniguez Ubiaga³⁷, Eva salgado-Pérez³⁸, Vicente Torrente Segarra³⁹, CARLOS TAREK SALMAN MONTE⁴⁰, JOSE ELOY OLLER RODRIGUEZ⁴¹ and José María Pego-Reigosa⁴², ¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²Hospital Sierrallana, Santander, Spain, ³Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁴Buenos Aires Instituto, West Reading, CA, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Universitario Donostia, San Sebastian, Spain, ¹⁶⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁹University Clinical Hospital of Canarias, Tenerife, Spain, ²⁰Son Llàtzer University Hospital, Palma de Mallorca, Spain, ²¹Hospital Sierrallana, CANTABRIA, Spain, ²²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Hospital Ramón y Cajal, Madrid, Spain, ²⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁶Virgen Macarena University Hospital,, Sevilla, Spain, ²⁷Hospital Insular de Gran Canaria, Las palmas, ²⁸Hospital León, LEON, Castilla y Leon, Spain, ²⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³²Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Infanta Sofia Hospital, Madrid, Spain, ³⁵Hospital Clínico Universitario Virgen de la Arrixaca,, Murcia, Spain, ³⁶La Paz University Hospital, Alcalá De Henares, Spain, ³⁷SERV. REUMATOLOGIA, Lugo, Spain, ³⁸Complejo Hospitalario de Orense, Santiago de Composte, Spain, ³⁹Hospital Comarcal del Alt Penedes, Madrid, Spain, ⁴⁰Hospital del Mar, Barcelona, Spain, ⁴¹HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁴²Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where…
Abstract Number: 0076 • ACR Convergence 2025
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Emma Weis¹, Harlan Sayles¹, Geoffrey Thiele¹, Samir Rachid Zaim², Tony Merriman³, Bryant England¹, Xiaojun Li², LauraKay Moss⁴, Jess Edison⁵, Marie Feser⁴, V. Michael Holers⁶, Kevin Deane⁷, Ted Mikuls¹ and Austin Wheeler¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Allen Institute for Immunology, Seattle, WA, ³University of Alabama at Birmingham, Homewood, AL, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Dawn Gist¹, Andrea Ramirez¹, Jamie Lai², Duc Nguyen¹ and Kexin Guo¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, The Woodlands, TX
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
Abstract Number: 0626 • ACR Convergence 2025
Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Nalani Sachan¹, Philip Carlucci², Mala Masson³, Nicola Fraser¹, Peter Izmirly⁴, Camila Hernández-Blanco⁵, Robert Clancy⁶, Bettina Cuneo⁷ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶Columbia University, New York, NY, ⁷University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: For childbearing women with SLE and other autoimmune diseases, the nearly invariant association of cardiac-NL with maternal SSA/Ro52/60kD autoantibodies supports the necessity of these…
Abstract Number: 1168 • ACR Convergence 2025
Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
Karis Lee¹, Min Kyung Lee² and Stanley Naides³, ¹Labcorp, Orlando, FL, ²Labcorp, Durham, NC, ³Labcorp, Dana Point, CA

Background/Purpose: Interstitial lung disease (ILD) is frequent in systemic autoimmune rheumatic diseases (SARDs) and is associated with poor prognosis. The prevalence of ILD is approximately…
Abstract Number: 1588 • ACR Convergence 2025
Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study
Vijaya prasanna Parimi¹, Tejaswini Ramineni², Pradeep S Anand³, Vineeta Shobha⁴, Padmanabha Shenoy⁵, Geetabali Sircar⁶, kaushik Basu⁷, Anna C Das⁴, Geetha Amritrao Kale⁴, indranil sarkar⁸, Shinie Razil Goveas⁴, Biswarup Sengupta⁸, Caseena Kareem⁹, Yogananth Sakthivel⁴, Soma Halder Biswas⁷ and Neel Nallulwar⁸, ¹ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ²Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India, ³ESIC MEDICAL COLLEGE AND HOSPITAL, HYDERABAD, Telangana, India, ⁴St. John's Medical College Hospital, Bangalore, Bangalore, Karnataka, India, ⁵Shenoy's CARE, Kochi, Kerala, India, ⁶West Bengal Medical Education Service, Kolkata, West Bengal, India, ⁷Medical College, Kolkata, kolkata, West Bengal, India, ⁸IPGMER, Kolkata, kolkata, West Bengal, India, ⁹CARE, Kochi, kochi, Kerala, India
Background/Purpose: Systemic sclerosis (SSC) is a chronic, multisystem autoimmune disease characterized by immune dysfunction, microangiopathy, and tissue remodelling. Orofacial manifestations, including xerostomia, microstomia, tooth decay,…
Abstract Number: 2059 • ACR Convergence 2025
Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)
Fabricio Benavides Villanueva¹, Ligia Gabrie-Rodriguez², Carmen Secada-Gómez³, Mayra Garcia⁴, Hector Ulloa-Alvarado⁵, Giuliano Boselli⁶, Camilo Veloza-Morales⁷, juan Irure-Ventura⁸, Marcos López-Hoyos⁹, Diana Prieto-Peña¹⁰ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Cantabria, Spain, ⁵Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁶Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁷Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁹Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases characterized by muscle inflammation and systemic involvement, often associated with specific autoantibodies. Immunoblot…
Abstract Number: 2432 • ACR Convergence 2025
Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
valerie Lewis¹, Faith Porter², Victoria Nwankwo³, John Ice⁴, Joshua Cavett⁵ and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Langston University, Langton, OK, ³Emory University, Atlanta, GA, ⁴OKC VA Healthcare System, Oklahoma City, OK, ⁵Oklahoma Medicar Research Foundtion, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) is a common, complex inflammatory autoimmune disease in which dysregulation of both innate and adaptive immune responses has been implicated…
Abstract Number: 0117 • ACR Convergence 2025
Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?
Cristina Rocamora-Gisbert¹, Francina salabert-Carreras², Raquel Ugena-García³, Cristina Calomarde-Gómez³, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Laia Gifre-Sala², Agueda Prior-Español², Annika Nack¹, Susana Holgado⁴, Maria Aparicio¹, Melania Martínez-Morillo², LOURDES MATEO SORIA⁵, Anne Riveros frutos¹, Ivette Casafont-Solé³ and Judit Font-Urgelles³, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁵HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain
Background/Purpose: It is known that triple positive antiphospholipid syndrome (APS-TP) is related to an increased presence of thrombotic and obstetric manifestations. Triple positivity is referred…
Abstract Number: 0467 • ACR Convergence 2025
A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) enables prompt intervention, significantly mitigating risk for disease progression, joint damage, and associated morbidity. Conventional biomarkers, anti-CCP and…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].